Japan's Takeda Pharma inks haematology deal worth $300 M with US-based Protagonist Therapeutics
Japan, Feb. 2 -- based pharmaceutical firm Takeda and US-based Protagonist Therapeutics have inked a global license and collaboration agreement for the development and commercialisation of rusfertide, an investigational injectable hepcidin mimetic peptide designed to mimic the natural hormone hepcidin.
Rusfertide is currently undergoing a pivotal Phase 3 trial, VERIFY, for the treatment of Polycythemia Vera (PV), a rare chronic blood disorder characterised by the overproduction of red blood cells, affecting approximately 160,000 patients in the US and a similar number in Europe.
As per the agreement's terms, Protagonist will receive an upfront payment of $300 million, along with potential additional payments linked to global development...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.